Design Therapeutics (DSGN) Payables (2020 - 2026)

Design Therapeutics has disclosed Payables across 7 years of filings, most recently posting $2.3 million for Q1 2026.

• Payables for Q1 2026 came in at $2.3 million, down 54.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.3 million (down 54.98% YoY), and the FY2025 annual result was $10.7 million, up 391.45% from the prior year.
• Payables came in at $2.3 million for Q1 2026 at Design Therapeutics, down from $10.7 million in the prior quarter.
• In the past five years, Payables ranged from a high of $10.7 million in Q4 2025 to a low of $1.0 million in Q2 2025.
• The 5-year median for Payables is $5.1 million (2025), against an average of $4.7 million.
• Across the five-year window, Payables jumped 393.05% in 2023 and plunged 80.13% in 2025, its largest moves.
• Design Therapeutics' Payables stood at $7.8 million in 2022, then sank by 74.97% to $1.9 million in 2023, then increased by 12.68% to $2.2 million in 2024, then soared by 391.45% to $10.7 million in 2025, then slumped by 78.81% to $2.3 million in 2026.
• The last three Payables figures came in at $2.3 million (Q1 2026), $10.7 million (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.